CLENE NANOMEDICINE
Clene Nanomedicine is a clinical-stage biopharmaceutical company that focuses on the development of unique therapeutics for neurodegenerative diseases. The company innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.
CLENE NANOMEDICINE
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2013-01-01
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.clene.com
Total Employee:
11+
Status:
Active
Contact:
801-676-9695
Total Funding:
121.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Accera
Accera is a biotechnology company that engages in the discovery and development of therapeutic drugs for neurodegenerative diseases.
Aclipse Therapeutics
Aclipse Therapeutics focuses on developing differentiated drugs to address diseases with unmet medical needs.
Actuate Therapeutics
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.
Adagio Medical
Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Anjarium Biosciences
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Fimecs
FIMECS is a focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.
HebeCell
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
KalGene Pharmaceuticals
KalGene Pharmaceuticals is a biotech company that develops precision medicine therapeutics for patients suffering from Alzheimer's disease.
LSK BioPharma
LSK BioPharma specializes in clinical development of promising therapies for unmet medical needs in cancer.
Mojave Pharma
Mojave Pharma focuses on the research of novel therapies for neurodegenerative & psychiatric diseases.
Neurimmune Holding
Neurimmune develops innovative immunotherapeutics for human diseases.
Neurotrope Bioscience
Neurotrope Bioscience engages in the development of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases.
Open Innovation Partners
Open Innovation Partners focuses on the development of cancer therapeutic agents.
PharmatrophiX
PharmatrophiX is a biotech company focused on developing therapeutic drugs to prevent neurodegenerative diseases.
Qlaris Bio
Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases.
QureBio
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Spinogenix
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases.
Synaps Dx
Synaps Dx focuses on the research, development and commercialization for neurodegenerative disorders including Alzheimer’s Disease.
Synapse Medicine
Synapse Medicine provides medication decision solutions to deliver enhanced patient-centered insights for care teams.
Tabomedex Biosciences, Inc.
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
AlloVir
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Westlake Therapeutics
The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
Current Employees Featured
Mark Mortenson Founder @ Clene Nanomedicine
Founder
Michael Hotchkin Chief Development Officer @ Clene Nanomedicine
Chief Development Officer
2017-10-01
Robert Glanzman Chief Medical Officer @ Clene Nanomedicine
Chief Medical Officer
2019-06-01
Rob Etherington CEO @ Clene Nanomedicine
CEO
2013-04-01
Ted Jeong Chief Financial Officer @ Clene Nanomedicine
Chief Financial Officer
2020-01-01
Founder
Stock Details
Investors List
Maryland Department of Housing and Community Development
Maryland Department of Housing and Community Development investment in Grant - Clene Nanomedicine
SymBiosis LLC
SymBiosis LLC investment in Post-IPO Equity - Clene Nanomedicine
SymBiosis LLC
SymBiosis LLC investment in Series D - Clene Nanomedicine
National Multiple Sclerosis Society (NMSS)
National Multiple Sclerosis Society (NMSS) investment in Grant - Clene Nanomedicine
FightMND
FightMND investment in Grant - Clene Nanomedicine
Official Site Inspections
http://www.clene.com Semrush global rank: 3.38 M Semrush visits lastest month: 4.65 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Clene Nanomedicine"
About Us | Clene Inc.
Prior to joining Clene, Ms. McNeil served as the EVP of Human Resources, Marketing and Sales for a successful art business, where she executed a company culture of diversity, career development, and an outstanding sales …See details»
Board of Directors | Clene Inc.
David Matlin has been on our board of directors since December 2020 and chairman of our board since May 2021, and is in charge of supervising and providing independent judgement to our …See details»
Clene Nanomedicine - Crunchbase Company Profile
Clene Nanomedicine is a clinical-stage biopharmaceutical company that focuses on the development of unique therapeutics for neurodegenerative diseases. …See details»
Clene Inc. - Press Releases
Feb 25, 2025 The Investor Relations website contains information about Clene Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Clene Inc. (CLNN) Company Profile & Facts - Yahoo Finance
See the company profile for Clene Inc. (CLNN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Clene Reports Full Year 2024 Financial Results and Recent …
3 days ago Full Year 2024 Financial Results Clene’s cash, cash equivalents and marketable securities totaled $12.2 million as of December 31, 2024, compared to $35.0 million as of …See details»
Clene Inc. (CLNN): history, ownership, mission, how it works
Discover Clene Inc.s mission, history, and revenue model. Learn how it sustains growth and revenue in the competitive biotech market.See details»
Clene Inc. - Clene Provides Update on Its NIH-Funded Expanded …
May 28, 2024 Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical …See details»
Clene to Participate in Jones Las Vegas Technology and Innovation ...
2 days ago Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical …See details»
Clene Nanomedicine - Funding, Financials, Valuation & Investors
Clene Nanomedicine is funded by 5 investors. National Institutes of Health and Maryland Department of Housing and Community Development are the most recent investors.See details»
Clene Reports Full Year 2024 Financial Results and Recent …
3 days ago Full Year 2024 Financial Results Clene’s cash, cash equivalents and marketable securities totaled $12.2 million as of December 31, 2024, compared to $35.0 million as of …See details»
Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct ...
Oct 10, 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial …See details»
Clene Inc. - News
Aug 9, 2024 The Investor Relations website contains information about Clene Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Clene Reports Full Year 2024 Financial Results and Recent
2 days ago Full Year 2024 Financial Results Clene’s cash, cash equivalents and marketable securities totaled $12.2 million as of December 31, 2024, compared to $35.0 million as of …See details»
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company
Aug 28, 2024 Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily …See details»
Clene to Present at the 37TH Annual Roth Conference
Mar 6, 2025 Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical …See details»
Morgan Brown | Clene Inc.
In his roles prior to Clene, Mr. Brown has participated in and led efforts to successfully evaluate, negotiate, and close transactions including equity and debt financings totaling over $1 billion …See details»
Clene to Participate in Jones Las Vegas Technology and Innovation ...
2 days ago Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical …See details»
Science | Clene Inc.
The Science By transmitting thousands of energy-supportive electrons per second per nanocrystal, CNM-Au8® rapidly catalyzes NAD+. This catalytic reaction drives production of …See details»
Clene (CLNN) Earnings Date and Reports 2025 - MarketBeat
3 days ago When is Clene's next earnings announcement? View the latest CLNN earnings date, analysts forecasts, earnings history, and conference call transcripts.See details»